Lumenis (LMNS) Tops Q3 EPS by 3c, Updates FY14 Guidance

Lumenis (NASDAQ: LMNS) reported Q3 EPS of $0.17, $0.03 better than the analyst estimate of $0.14. Revenue for the quarter came in at $74.2 million versus the consensus estimate of $71.9 million.

Lumenis sees FY2014 EPS of $0.51-$0.55, versus the consensus of $0.53. Lumenis sees FY2014 revenue of $285-287 million, versus prior guidance of $284-287 million and the consensus of $286 million.

For earnings history and earnings-related data on Lumenis (LMNS) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Dare Bioscience (DARE) Tops Q2 EPS by 11c